Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease

References

• Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990;335: 1078–1080.
   PubMed Web of Science ®Google Scholar
• Dinning W. An overview of ocular manifestations. In: Lehner T, Barnes C, editors. Recent Advances in Beh�et�s Disease. London: Royal Society of Medicine Service, 1986;227–233.
   Google Scholar
• Ando K, Fujino Y, Hijikata K, et al. Epidemiological features and visual prognosis of Behcet's disease. Jpn J Ophthalmol 1999;43:312–317.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Akazawa K, Nishioka Y, et al. Prognostic factors of vision in patients with Behcet disease. Ophthalmology 1995;102:317–321.
   PubMed Web of Science ®Google Scholar
• Demiroglu H, Barista I, Dundar S. Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey. Ophthalmology 1997;104:701–705.
   Google Scholar
• Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol 1994;118:39–45.
   PubMed Web of Science ®Google Scholar
• Sullu Y, Oge I, Erkan D, et al. Cyclosporin-A therapy in severe uveitis of Behcet's disease. Acta Ophthalmol Scand 1998;76:96–99.
   PubMedGoogle Scholar
• Reed JB, Morse LS, Schwab IR. High-dose intravenous pulse methylpred-nisolone hemisuccinate in acute Behcet retinitis. Am J Ophthalmol 1998;125:409–411.
   Google Scholar
• Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999; 106:723–728.
   Google Scholar
• Hayasaka S, Kawamoto K, Noda S, et al. Visual prognosis in patients with Behcet's disease receiving colchicine, systemic corticosteroid or cyclosporin. Ophthalmologica 1994; 208:210–213.
   Google Scholar
• Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye 1998;12:783–788.
   Google Scholar
• Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40: 769–774.
   PubMed Web of Science ®Google Scholar
• Cochereau-Massin I, Wechsler B, Le Hoang P, et al. Ocular prognosis in Behcet's disease. J Fr Ophtalmol 1992;15:343–347.
   Google Scholar
• Durand JM, Kaplanski G, Telle H, et al. Beneficial effects of interferon-alpha 2b in Behcet's disease. Arthritis Rheum 1993;36:1025–1026.
   Google Scholar
• Tsambaos D, Eichelberg D, Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986; 278:335–336.
   Google Scholar
• Pivetti-Pezzi P, Accorinti M, Pirraglia MP, et al. Interferon alpha for ocular Behcet's disease. Acta Ophthalmol Scand 1997;75:720–722.
   Google Scholar
• Kotter I, Eckstein AK, Stubiger N, et al. Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 1998;82:488–494.
   PubMed Web of Science ®Google Scholar
• Gross WL. New concepts in treatment protocols for severe systemic vasculitis. Curr Opin Rheumatol 1999;11:41–46.
   Google Scholar
• Georgiou S, Monastirli A, Pasmatzi E, et al. Efficacy and safety of systemic recombinant interferon-alpha in Behcet's disease. J Intern Med 1998;243:367–372.
   PubMed Web of Science ®Google Scholar
• Azizlerli G, Sarica R, Kose A, et al. Interferon alfa-2a in the treatment of Behcet's disease. Dermatology 1996; 192:239–241.
   PubMedGoogle Scholar
• Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2h treatment in Behcet's syndrome. J Rheumatol 1994;21:1098-110o.
   Google Scholar
• O'Duffy JD, Calamia K, Cohen S, et al. Interferon-alpha treatment of Behcet's disease. J Rheumatol 1998; 25:1938–1944.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Orfanos CE. Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998;134:10I0–1016.
   Google Scholar
• Pesce A, Chichmanian R, Vinti H, et al. Interferon alpha2 and ocular toxicity. Rev Med Interne Suppl 1995; 16:5o1S.
   Google Scholar
• Manesis EK, Petrou C, Brouzas D, et treatment. J Hepatol 1994;21:474–477.
   PubMed Web of Science ®Google Scholar
• Yamada H, Mizobuchi K, Isogai Y. Acute onset of ocular complications Acute onset of ocular complications with interferon [letter]. Lancet 1994; 343:914.
   Google Scholar
• Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995;79:150–152.
   PubMed Web of Science ®Google Scholar
• Kadayifcilar S, Boyacioglu S, Kart H, et al. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye 1999;13:241–246.
   PubMed Web of Science ®Google Scholar
• Alric L, Izopet J, Fort M, et al. Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Hum Immunol 1999;60: 516–523.
   PubMed Web of Science ®Google Scholar
• Kakizaki S, Takagi H, Murakami M, et al. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol 1999;30:794–800.
   PubMed Web of Science ®Google Scholar
• Knolle PA, Kremp S, Hohler T, et al. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. J Viral Hepat 1998;5:399–406.
   Google Scholar
• Kosar A, Haznedaroglu S, Karaaslan Y, et al. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behcet's disease. Rheumatol Int 1999;19:11–14.
   PubMedGoogle Scholar